Maarten O. Blanken

Maarten O. Blanken

Auto-generated profile, based on publicly available information

Maarten O. Blanken

Division of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, P.O. Box 85090, 3508 AB, Utrecht, the Netherlands

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MBMaarten O. Blanken
Maarten O. Blanken
MRMaroeska M. Rovers
Maroeska M. Rovers
JMJorine M. Molenaar
Jorine M. Molenaar
PWPauline L. Winkler-Seinstra
Pauline L. Winkler-Seinstra
AMAdam Meijer
Adam Meijer
LBLouis Bont
Louis Bont
Respiratory syncytial virus (RSV) infection is associated with subsequent recurrent wheeze. Observational studies cannot determine whether RSV infection is the cause of recurrent wheeze or the first indication of preexistent pulmonary vulnerability in preterm infants. The monoclonal antibody palivizumab has shown efficacy in preventing severe RSV infection in high-risk infants.

1 November 2009 in Clinical Immunology
Verified
Journal Article
Closed access
MBM.E. Belderbos
M.E. Belderbos
GBG.M. van Bleek
G.M. van Bleek
OLOfer Levy
Ofer Levy
MBM.O. Blanken
M.O. Blanken
MHM.L. Houben
M.L. Houben
LBL. Bont
L. Bont

24 March 2017 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
NANiek B Achten
Niek B Achten
PWPingsheng Wu
Pingsheng Wu
LBLouis Bont
Louis Bont
MBMaarten O. Blanken
Maarten O. Blanken
TGTebeb Gebretsadik
Tebeb Gebretsadik
THTina Hartert
Tina Hartert
Respiratory syncytial virus (RSV) and human rhinovirus (HRV) are the most common viruses associated with acute respiratory tract infections in infancy. Viral interference is important in understanding respiratory viral circulation and the impact of vaccines. To study viral interference, we evaluated cases of RSV and HRV codetection by polymerase chain reaction in 2 prospective birth cohort studies (the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure [INSPIRE] study and the Tennessee Children’s Respiratory Initiative [TCRI]) and a double-blinded, randomized, controlled trial (MAKI), using adjusted multivariable regression analyses. Among 3263 respiratory tract samples, 24.5% (798) and 37.3% (1216) were RSV and HRV positive, respectively. The odds of HRV infection were significantly lower in RSV-infected infants in all cohorts, with adjusted odds ratios of 0.30 (95% confidence interval [CI], .22–.40 in the INSPIRE study, 0.18 (95% CI, .11–.28) in the TCRI (adjusted for disease severity), and 0.34 (95% CI, .16–.72) in the MAKI trial. HRV infection was significantly more common among infants administered RSV immunoprophylaxis, compared with infants who did not receive immunoprophylaxis (OR, 1.65; 95% CI, 1.65–2.39). A negative association of RSV on HRV codetection was consistently observed across populations, seasons, disease severity, and geographical regions. Suppressing RSV infection by RSV immunoprophylaxis might increase the risk of having HRV infection.

12 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMaarten O. Blanken
Maarten O. Blanken
HKHendrik Koffijberg
Hendrik Koffijberg
ENElisabeth E. Nibbelke
Elisabeth E. Nibbelke
MRMaroeska M. Rovers
Maroeska M. Rovers
LBLouis Bont
Louis Bont
ONOn Behalf Of The Dutch Rsv Neonatal Network
On Behalf Of The Dutch Rsv Neonatal Network
This study aimed to update and validate a prediction rule for respiratory syncytial virus (RSV) hospitalization in preterm infants 33–35 weeks gestational age (WGA). The RISK study consisted of 2 multicenter prospective birth cohorts in 41 hospitals. Risk factors were assessed at birth among healthy preterm infants 33–35 WGA. All hospitalizations for respiratory tract infection were screened for proven RSV infection by immunofluorescence or polymerase chain reaction. Multivariate logistic regression analysis was used to update an existing prediction model in the derivation cohort (n = 1,227). In the validation cohort (n = 1,194), predicted versus actual RSV hospitalization rates were compared to determine validity of the model. RSV hospitalization risk in both cohorts was comparable (5.7% versus 4.9%). In the derivation cohort, a prediction rule to determine probability of RSV hospitalization was developed using 4 predictors: family atopy (OR 1.9; 95%CI, 1.1–3.2), birth period (OR 2.6; 1.6–4.2), breastfeeding (OR 1.7; 1.0–2.7) and siblings or daycare attendance (OR 4.7; 1.7–13.1). The model showed good discrimination (c-statistic 0.703; 0.64–0.76, 0.702 after bootstrapping). External validation showed good discrimination and calibration (c-statistic 0.678; 0.61–0.74). Our prospectively validated prediction rule identifies infants at increased RSV hospitalization risk, who may benefit from targeted preventive interventions. This prediction rule can facilitate country-specific, cost-effective use of RSV prophylaxis in late preterm infants.

6 February 2018 in Pediatric Pulmonology
Verified
Journal Article
Open access
PDF file
MBMaarten O. Blanken
Maarten O. Blanken
BPBosco Paes
Bosco Paes
EAEvan J. Anderson
Evan J. Anderson
MLMarcello Lanari
Marcello Lanari
MSMargaret Sheridan‐Pereira
Margaret Sheridan‐Pereira
XCXavier Carbonell‐Estrany
Xavier Carbonell‐Estrany
Background: The objective was to develop a risk scoring tool which predicts respiratory syncytial virus hospitalisation (RSVH) in moderate‐late preterm infants (32‐35 weeks’ gestational age) in the Northern Hemisphere.Methods: Risk factors for RSVH were pooled from six observational studies of infants born 32 weeks and 0 days to 35 weeks and 6 days without comorbidity from 2000 to 2014. Of 13 475 infants, 484 had RSVH in the first year of life. Logistic regression was used to identify the most predictive risk factors, based on area under the receiver operating characteristic curve (AUROC). The model was validated internally by 100‐fold bootstrapping and externally with data from a seventh observational study. The model coefficients were converted into rounded multipliers, stratified into risk groups, and number needed to treat (NNT) calculated.Results: The risk factors identified in the model included (i) proximity of birth to the RSV season; (ii) second‐hand smoke exposure; and (iii) siblings and/or daycare. The AUROC was 0.773 (sensitivity: 68.9%; specificity: 73.0%). The mean AUROC from internal bootstrapping was 0.773. For external validation with data from Ireland, the AUROC was 0.707 using Irish coefficients and 0.681 using source model coefficients. Cut‐off scores for RSVH were ≤19 for low‐ (1.0%), 20‐45 for moderate‐ (3.3%), and 50‐56 (9.5%) for high‐risk infants. The high‐risk group captured 62.0% of RSVHs within 23.6% of the total population (NNT 15.3).Conclusions: This risk scoring tool has good predictive accuracy and can improve targeting for RSVH prevention in moderate‐late preterm infants.

22 August 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MBMaarten O Blanken
Maarten O Blanken
MRMaroeska M Rovers
Maroeska M Rovers
LBLouis Bont
Louis Bont
DNDutch Rsv Neonatal Network
Dutch Rsv Neonatal Network
In the randomized trial reported by Blanken et al. (May 9 issue),1 the reduction of 9.7 percentage points in recurrent wheezing corresponds to a number needed to treat of 10.3. The risk of hospitalization for respiratory syncytial virus (RSV) infection and other respiratory causes was 3.7% in the palivizumab group and 7.9% in the placebo group, corresponding to a number needed to treat of 23.8. These numbers are important because of the considerable cost involved in RSV prophylaxis (approximately $6,500 per immunized child per season). Thus, the costs of preventing one hospitalization for respiratory causes in this study total more than $154,000. Although a formal cost-effectiveness analysis may follow, it would have been worthwhile to provide the numbers needed to treat and the costs of treatment.